Pfizer to Pay for Off Label Drug Promotions

Pfizer Inc. has agreed to pay a $2.3 billion penalty to settle a civil suit over the drug company’s illegal promotional practices. The settlement is the largest ever for violations of federal law concerning a drug company’s promotion of a product for off-label use.
While it’s common and accepted practice for doctors to prescribe drugs for off-label use, it’s illegal for drug companies to promote their products for uses other than those approved by the FDA.
The $2.3 billion settlement concerns Pfizer’s promotion of Bextra as well as other Pfizer products.
The US Justice Deparment, along with the Department of Health and Human Services plan a news conference for later today to announce the historic settlement.